Request Demo
Last update 29 Mar 2025
Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)
Last update 29 Mar 2025
Overview
Basic Info
Drug Type Fab fragment, Biosimilar |
Synonyms Ranibizumab biosimilar, Ranibizumab(Genetical Recombination), RANIBIZUMABU BS INTRAVITREAL INJECTION KIT 10mg/mL(SENJU) + [8] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (27 Sep 2021), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 103170L
The sequence is quoted from: *****
Sequence Code 143622H
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)JPRN-UMIN000030010
A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degeneration - A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degeneration
NCT02259088
A 12-month, Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Dosed PRN in Subjects With Visual Impairment Due to Diabetic Macular Edema in Chinese Patients
EUCTR2014-000272-26-GB
A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion (CRVO). - LEAVO
100 Clinical Results associated with Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)
Login to view more data
1
Literatures (Medical) associated with Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)23 Oct 2006The Medical letter on drugs and therapeuticsQ4 · MEDICINE
Ranibizumab (Lucentis) for macular degeneration.
Q4 · MEDICINE
Review
100 Deals associated with Ranibizumab biosimilar(Senju Pharmaceutical Co., Ltd.)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Retinal vein occlusion-related macular edema | Japan | 27 Sep 2023 | |
| Diabetic macular oedema | Japan | 11 Jan 2023 | |
| Age Related Macular Degeneration | Japan | 27 Sep 2021 | |
| Choroidal Neovascularization | Japan | 27 Sep 2021 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Wet age-related macular degeneration | Preclinical | China | 30 Jan 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | iztsnkwhcz(spjlhdomoq) = dzxwhyxsem bjpvepthpv (bpbvldszdb ) | - | 19 Sep 2024 | |||
(Laser photocoagulation) | iztsnkwhcz(spjlhdomoq) = zfizevekoz bjpvepthpv (bpbvldszdb ) | ||||||
Phase 3 | 384 | Sham laser+Ranibizumab (RFB002) (Ranibizumab (RFB002)) | pfsxszbnkq(qrfcphxyld) = agkeeyfesv vcpxbaljkv (zzepnlcyur, 6.58) View more | - | 01 Feb 2019 | ||
Laser (Laser) | pfsxszbnkq(qrfcphxyld) = lelwtrlaey vcpxbaljkv (zzepnlcyur, 7.73) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free